Free Trial

Point72 Asset Management L.P. Sells 1,642,723 Shares of CureVac (NASDAQ:CVAC)

CureVac logo with Medical background

Point72 Asset Management L.P. lowered its holdings in shares of CureVac (NASDAQ:CVAC - Free Report) by 67.8% in the 3rd quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The fund owned 780,005 shares of the company's stock after selling 1,642,723 shares during the quarter. Point72 Asset Management L.P. owned approximately 0.35% of CureVac worth $2,293,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors have also recently made changes to their positions in the business. Private Advisor Group LLC purchased a new stake in CureVac during the third quarter valued at approximately $30,000. Integrated Wealth Concepts LLC purchased a new stake in shares of CureVac in the 3rd quarter worth $35,000. International Assets Investment Management LLC bought a new position in CureVac in the 3rd quarter worth $35,000. Bank of New York Mellon Corp purchased a new position in CureVac during the second quarter valued at $54,000. Finally, Ballentine Partners LLC grew its holdings in CureVac by 58.6% during the third quarter. Ballentine Partners LLC now owns 22,755 shares of the company's stock valued at $67,000 after purchasing an additional 8,406 shares during the period. Institutional investors own 17.26% of the company's stock.

CureVac Price Performance

Shares of CVAC traded down $0.11 during trading hours on Tuesday, reaching $3.26. 671,885 shares of the stock traded hands, compared to its average volume of 827,324. CureVac has a 52-week low of $2.21 and a 52-week high of $6.30. The company has a current ratio of 6.20, a quick ratio of 6.19 and a debt-to-equity ratio of 0.05. The company has a market cap of $729.85 million, a P/E ratio of 6.24, a price-to-earnings-growth ratio of 0.26 and a beta of 2.59. The company's 50-day moving average price is $2.82 and its two-hundred day moving average price is $3.22.

Wall Street Analyst Weigh In

Separately, JMP Securities reaffirmed a "market outperform" rating and issued a $16.00 price objective on shares of CureVac in a research note on Monday, September 16th.

Get Our Latest Analysis on CVAC

CureVac Company Profile

(Free Report)

CureVac N.V., a biopharmaceutical company, focuses on developing various transformative medicines based on messenger ribonucleic acid (mRNA). It is developing prophylactic vaccines, such as mRNA-based vaccine candidates CV2CoV, which is in Phase 1 clinical trial against SARS-CoV-2; CV7202 which is in Phase 1 clinical trial for the treatment of rabies; and CVSQIV to treat multivalent seasonal influenza; Flu SV mRNA fot treating nucleotides, single antigen seasonal influenza.

See Also

Institutional Ownership by Quarter for CureVac (NASDAQ:CVAC)

Should you invest $1,000 in CureVac right now?

Before you consider CureVac, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and CureVac wasn't on the list.

While CureVac currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

10 Best Cheap Stocks to Buy Now Cover

MarketBeat just released its list of 10 cheap stocks that have been overlooked by the market and may be seriously undervalued. Click the link below to see which companies made the list.

Get This Free Report
Like this article? Share it with a colleague.

Featured Articles and Offers

Recent Videos

Broadcom Hits $1 Trillion – Can This AI Powerhouse Go Higher?
SoundHound Stock Explodes Again – Is a Major Breakout Coming?
How Fintech Strategy at FinWise Bancorp and CEO Vision Are Driving 78% Gains

Stock Lists

All Stock Lists

Investing Tools

Calendars and Tools

Search Headlines